Abstract
An experimental, once-daily pill for hepatitis C virus (HCV) leads to high rates of sustained virologic response across a wide range of patients, according to findings from four international, industry-supported, phase III trials reported below. The pill combines sofosbuvir (400 mg) with velpatasvir (100 mg; a novel pan-genotypic HCV NS5A inhibitor). The primary endpoint in all studies was sustained virologic response at 12 weeks after treatment ended (SVR12). Some 700 patients with HCV genotypes 1, 2, 4, and 6 were randomized to receive sofosbuvir–velpatasvir or placebo for 12 weeks; …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
